title: Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin.
abstract: BACKGROUND
  Patients with severe visual loss because of optic neuritis refractory to high dose corticosteroids have limited therapeutic options. The use of intravenous immunoglobulin (IVIG) has been advocated in the past, but data are scarce. In this study, we use a protocol different from those used in other studies, with different timing and dosage.
  
  
  METHODS
  Consecutive patients with corticosteroid-refractive optic neuropathy were treated with IVIG and compared with control patients who received only corticosteroids in an open-label, non-randomized, controlled prospective study.
  
  
  RESULTS
  Twenty-three patients received treatment with IVIG and 24 matched patients who did not receive treatment with IVIG were followed as controls. All patients had visual acuity 20/400 or worse in the affected eye. There was significant improvement in the IVIG group with 18/23 (78%) subjects reaching near normal vision (20/30 or better), compared with the control group with only 3/24 (12.5%) responding similarly.
  
  
  CONCLUSIONS
  The use of IVIG, following corticosteroids, may be useful using the protocol described herein, with sustained pulsed dosing. A larger controlled trial is indicated to confirm these results.
authors: Department of Neurology, Multiple Sclerosis Clinical Research Center, Detroit, MI, USA.
authors: A
authors: A
authors: Tselis
authors: J
authors: J
authors: Perumal
authors: C
authors: C
authors: Caon
authors: S
authors: S
authors: Hreha
authors: W
authors: W
authors: Ching
authors: M
authors: M
authors: Din
authors: G
authors: G
authors: Van Stavern
authors: O
authors: O
authors: Khan
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004185:Disability Evaluation; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000187:drug effects* / Q000276:immunology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D009103:Multiple Sclerosis / Q000150:complications* / Q000276:immunology; D009900:Optic Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D009902:Optic Neuritis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors